Lytix Biopharma AS – Licensing partner Verrica Pharmaceuticals presents clinical data with LTX-315 at the 2025 Winter Clinical Dermatology Conference
Oslo, Norway, January 22, 2025 – Lytix Biopharma’s licensing partner, Verrica Pharmaceuticals, has presented clinical data on Lytix lead drug candidate, LTX-315, at the 2025 Winter Clinical Dermatology Conference held January 17-19 in Miami, Florida. The results support a potential change in the treatment paradigm for patients with basal cell carcinoma. The three posters presented by Verrica at the conference highlighted positive clinical data from Part 2 of the Phase 2 study of LTX-315 (named VP-315 by Verrica), a novel oncolytic peptide therapy for the treatment of basal cell